Several IDH inhibitors, approved by the FDA for other malignancies, are under investigation for IDH-mutant gliomas, including ivosidenib, olutasidenib, and safusidenib (mutant IDH1 inhibitors) and enasidenib (mutant IDH2 inhibitor). Here, IDH1 is linked to glioma.